Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
||
| Line 17: | Line 17: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/dacarbazine.aspx Dacarbazine (DTIC) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dacarbazine-patient-drug-information Dacarbazine (DTIC) patient drug information (UpToDate)]</ref> | ||
Revision as of 22:03, 16 December 2021
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Leiomyosarcoma
- Liposarcoma
- Melanoma
- Pheochromocytoma
- Soft tissue sarcoma
- Uveal melanoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/27/1975: Initial FDA approval
Also known as
- Generic names: dacarbazin, DTIC, imidazole carboxamide
- Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Alkylating agents
- Triazenes
- Human DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Leiomyosarcoma medications
- Liposarcoma medications
- Melanoma medications
- Pheochromocytoma medications
- Soft tissue sarcoma medications
- Uveal melanoma medications
- FDA approved in 1975
- WHO Essential Cancer Medicine